| MYO6 contributes to tumor progression and enzalutamide resistance in castration-resistant prostate cancer by activating the focal adhesion signaling pathway. | MYO6 contributes to tumor progression and enzalutamide resistance in castration-resistant prostate cancer by activating the focal adhesion signaling pathway.
Zheng S, Hong Z, Tan Y, Wang Y, Li J, Zhang Z, Feng T, Hong Z, Lin G, Ye D., Free PMC Article | 10/25/2024 |
| Targeted Next-Generation Sequencing Analysis Reveals a Novel Genetic Variant in MYO6 Gene in an Indian Family with Postlingual Nonsyndromic Hearing Loss. | Targeted Next-Generation Sequencing Analysis Reveals a Novel Genetic Variant in MYO6 Gene in an Indian Family with Postlingual Nonsyndromic Hearing Loss.
Raghuvanshi R, Panda KC, Ray CS, Ramchander PV. | 09/20/2024 |
| How myosin VI traps its off-state, is activated and dimerizes. | How myosin VI traps its off-state, is activated and dimerizes.
Canon L, Kikuti C, Planelles-Herrero VJ, Lin T, Mayeux F, Sirkia H, Lee YI, Heidsieck L, Velikovsky L, David A, Liu X, Moussaoui D, Forest E, Höök P, Petersen KJ, Morgan TE, Di Cicco A, Sirés-Campos J, Derivery E, Lévy D, Delevoye C, Sweeney HL, Houdusse A., Free PMC Article | 10/28/2023 |
| LncRNA UCA1 promotes development of gastric cancer via the miR-145/MYO6 axis. | LncRNA UCA1 promotes development of gastric cancer via the miR-145/MYO6 axis.
Yang A, Liu X, Liu P, Feng Y, Liu H, Gao S, Huo L, Han X, Wang J, Kong W., Free PMC Article | 02/5/2022 |
| Dynamic multimerization of Dab2-Myosin VI complexes regulates cargo processivity while minimizing cortical actin reorganization. | Dynamic multimerization of Dab2-Myosin VI complexes regulates cargo processivity while minimizing cortical actin reorganization.
Rai A, Vang D, Ritt M, Sivaramakrishnan S., Free PMC Article | 08/28/2021 |
| A dynamic Dab2 keeps myosin VI stably on track. | A dynamic Dab2 keeps myosin VI stably on track.
Cirilo JA Jr, Yengo CM., Free PMC Article | 08/14/2021 |
| Clinical Characteristics and In Vitro Analysis of MYO6 Variants Causing Late-Onset Progressive Hearing Loss. | Clinical Characteristics and In Vitro Analysis of MYO6 Variants Causing Late-Onset Progressive Hearing Loss.
Oka SI, Day TF, Nishio SY, Moteki H, Miyagawa M, Morita S, Izumi S, Ikezono T, Abe S, Nakayama J, Hyogo M, Okamoto N, Uehara N, Oshikawa C, Kitajiri SI, Usami SI., Free PMC Article | 02/2/2021 |
| Competition between two high- and low-affinity protein-binding sites in myosin VI controls its cellular function. | Competition between two high- and low-affinity protein-binding sites in myosin VI controls its cellular function.
Fili N, Hari-Gupta Y, Aston B, Dos Santos Á, Gough RE, Alamad B, Wang L, Martin-Fernandez ML, Toseland CP., Free PMC Article | 09/19/2020 |
| A humanized mouse model, demonstrating progressive hearing loss caused by MYO6 p.C442Y, is inherited in a semi-dominant pattern. | A humanized mouse model, demonstrating progressive hearing loss caused by MYO6 p.C442Y, is inherited in a semi-dominant pattern.
Wang J, Shen J, Guo L, Cheng C, Chai R, Shu Y, Li H. | 09/19/2020 |
| We identified and classified a pathogenic GFI1 variant and a likely pathogenic variant in MYO6 which together explain the complex phenotypes seen in this family. | Two monogenic disorders masquerading as one: severe congenital neutropenia with monocytosis and non-syndromic sensorineural hearing loss.
Venugopal P, Gagliardi L, Forsyth C, Feng J, Phillips K, Babic M, Poplawski NK, Rienhoff HY Jr, Schreiber AW, Hahn CN, Brown AL, Scott HS., Free PMC Article | 03/7/2020 |
| There is coordinated action of myosin VI and CLCa at the apical surface where these proteins are essential for fission of clathrin-coated pits. Myosin VI and Huntingtin-interacting protein 1-related protein (Hip1R) are mutually exclusive interactors with CLCa, and suggest a model for the sequential function of myosin VI and Hip1R in actin-mediated clathrin-coated vesicle budding. | Clathrin light chain A drives selective myosin VI recruitment to clathrin-coated pits under membrane tension.
Biancospino M, Buel GR, Niño CA, Maspero E, Scotto di Perrotolo R, Raimondi A, Redlingshöfer L, Weber J, Brodsky FM, Walters KJ, Polo S., Free PMC Article | 03/7/2020 |
| two mutations, one in MYO6 (c.554-1 G > A) gene and another in PJVK (c.547C > T) are responsible for 1% each of the Iranian ARNSHL patients | Targeted Mutation Analysis of the SLC26A4, MYO6, PJVK and CDH23 Genes in Iranian Patients with AR Nonsyndromic Hearing Loss.
Alimardani M, Hosseini SM, Khaniani MS, Haghi MR, Eslahi A, Farjami M, Chezgi J, Derakhshan SM, Mojarrad M. | 12/14/2019 |
| New missense variants of MYO6 in the Korean autosomal dominant deaf patients.MYO6 variants showed a wide array of auditory phenotypes, including the age of onset and audiogram configurationsin the Korean autosomal dominant deaf patients. | A clinical guidance to DFNA22 drawn from a Korean cohort study with an autosomal dominant deaf population: A retrospective cohort study.
Kim BJ, Han JH, Park HR, Kim MY, Kim AR, Oh SH, Park WY, Oh DY, Lee S, Choi BY. | 09/28/2019 |
| Myosin VI, together with branched actin filaments, constricts the membrane of tubular carriers that are then released from melanosomes, the pigment containing lysosome-related organelles of melanocytes. | Myosin VI and branched actin filaments mediate membrane constriction and fission of melanosomal tubule carriers.
Ripoll L, Heiligenstein X, Hurbain I, Domingues L, Figon F, Petersen KJ, Dennis MK, Houdusse A, Marks MS, Raposo G, Delevoye C., Free PMC Article | 07/20/2019 |
| Myosin VI is involved in the pigment epithelium phagocytosis and rafficking of phagosomes. | A role for myosin VI in retinal pigment epithelium phagocytosis.
Hewage N, Altman D. | 06/1/2019 |
| results demonstrate that miR-5195-3p functions as a tumor suppressor by directly modulating MYO6 expression in NSCLC cells, and may be an innovative candidate target for NSCLC therapy | MicroRNA-5195-3p plays a suppressive role in cell proliferation, migration and invasion by targeting MYO6 in human non-small cell lung cancer.
Yang Q. | 04/6/2019 |
| We identified a novel missense mutation of MYO6 in a Chinese family with autosomal dominant non-syndromic hearing loss, and conducted a preliminary analysis of the potential molecular pathogenesis of a myosin VI deafness mutation (p.K208E). This novel mutation expands the mutational spectrum of MYO6, and will contribute to a deeper understanding of the association between NSHL etiology and MYO6 mutations. | Identification of a novel MYO6 mutation associated with autosomal dominant non-syndromic hearing loss in a Chinese family by whole-exome sequencing.
Tian T, Lu Y, Yao J, Cao X, Wei Q, Li Q. | 03/2/2019 |
| Backfolding of MVI regulates its ability to bind DNA and that a putative transcription co-activator NDP52 relieves the auto-inhibition of MVI to enable DNA binding. Additionally, we show that the MVI-NDP52 complex binds RNAPII, which is critical for transcription, and that depletion of NDP52 or MVI reduces steady-state mRNA levels. | NDP52 activates nuclear myosin VI to enhance RNA polymerase II transcription.
Fili N, Hari-Gupta Y, Dos Santos Á, Cook A, Poland S, Ameer-Beg SM, Parsons M, Toseland CP., Free PMC Article | 10/6/2018 |
| The tumorigenic effect of lncRNA SOX21-AS1 in CRC cells via targeting miR-145/MYO6, providing a novel insight for CRC carcinogenesis. | Long non-coding RNA SOX21-AS1 sponges miR-145 to promote the tumorigenesis of colorectal cancer by targeting MYO6.
Wei AW, Li LF. | 07/28/2018 |
| Rab33b, OATL1 and Myo6 have roles in nanoparticle trafficking in HeLa cells | A systematic High-Content Screening microscopy approach reveals key roles for Rab33b, OATL1 and Myo6 in nanoparticle trafficking in HeLa cells.
Panarella A, Bexiga MG, Galea G, O' Neill ED, Salvati A, Dawson KA, Simpson JC., Free PMC Article | 07/7/2018 |
| miR-143 and miR-145 suppress gastric cancer cell migration and metastasis by inhibiting MYO6 expression and the epithelial-mesenchymal transition, which provides a novel mechanism and promising therapeutic target for the treatment of gastric cancer metastasis. | miR-143 and miR-145 inhibit gastric cancer cell migration and metastasis by suppressing MYO6.
Lei C, Du F, Sun L, Li T, Li T, Min Y, Nie A, Wang X, Geng L, Lu Y, Zhao X, Shi Y, Fan D., Free PMC Article | 06/9/2018 |
| MYO6 facilitates Salmonella invasion.Salmonella virulence effector SopB requires MYO6 to regulate the localization of phosphoinositides and Akt activation. | MYO6 is targeted by Salmonella virulence effectors to trigger PI3-kinase signaling and pathogen invasion into host cells.
Brooks AB, Humphreys D, Singh V, Davidson AC, Arden SD, Buss F, Koronakis V., Free PMC Article | 05/26/2018 |
| Data indicate filopodia formation and MYO6 motor function at endosomes and at the plasma membrane. | Filopodia formation and endosome clustering induced by mutant plus-end-directed myosin VI.
Masters TA, Buss F., Free PMC Article | 05/12/2018 |
| we describe a novel nonsense MYO6 mutation that was responsible for the hearing loss in a Brazilian family | Exome Sequencing Identifies a Novel Nonsense Mutation of MYO6 as the Cause of Deafness in a Brazilian Family.
Sampaio-Silva J, Batissoco AC, Jesus-Santos R, Abath-Neto O, Scarpelli LC, Nishimura PY, Galindo LT, Bento RF, Oiticica J, Lezirovitz K. | 01/6/2018 |
| this is the first ILDR1 and MYO6 mutations recognized in the southwest Iran. Our data expands the spectrum of mutations in ILDR1 and MYO6 genes | Next-generation sequencing identifies three novel missense variants in ILDR1 and MYO6 genes in an Iranian family with hearing loss with review of the literature.
Talebi F, Mardasi FG, Asl JM, Sayahi M. | 12/30/2017 |